Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

H&M teams up with Coloreel to bring personalized embroidery to Berlin

The global fashion retailer H&M has joined forces with Coloreel to introduce a pioneering approach to customized embroidery. This new partnership allows customers at the H&M Alexa store in Berlin to personalize their apparel with a myriad of expressive designs.The program marks the start of a new and innovative in-store pilot developed by H&Mbeyond. Customers can select from a diverse library of designs that will be updated on a weekly basis. Coloreel redefines the art of embroidery, offering an unlimited spectrum of colors at the touch of a button. The technology reduces wastewater by a

Invitation to presentation of Eastnine's interim report January-September 2023

Eastnine invites investors, analysts and media to a live presentation of the interim report January-September on Thursday 26 October 2023, at 10.00 (CET). The report is expected to be made public the same day at 07.00 (CET).   Time for the webcast Thursday 26 October 2023, at 10.00 (CET)   Click here  to see the webcast.   Please join the event a few minutes before the presentation begins. An investor presentation will be available at www.eastnine.com 15 minutes before the start of the webcast. A recording of the webcast will

Abstract presented at the 11th Trends in Medical Mycology publicly available

Stockholm, Sweden – October 23, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, today announced that the company’s abstract about the drug candidate BSG005, which was presented at the 11th Trends in Medical Mycology, on October 21, 2023, is now publicly availableThe abstract presentation, given by Biosergen’s COO Tine Olesen, laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the

Secure your spot at BioStock Life Science Fall Summit - tickets are running out!

This Wednesday and Thursday, it is finally time for the 6th annual BioStock Life Science Fall Summit! The packed two-day event will take place LIVE, at Medicon Village in Lund, featuring over 40 life science companies showcasing their projects and innovations to investors and potential partners. The Summit also gives space for panel discussions and live interviews where industry experts and investors will offer their valuable advice and experiences.•                                        Where? Medicon Village, Lund •                                        When? October 25-26, 2023. •

Avinor chooses Telia Norway as its 5G pilot partner

Avinor, the state-owned limited company that operates most of the civil airports in Norway, has chosen to partner with Telia Norway to explore how 5G technologies can be used to digitize and streamline airport operations, while also making them more sustainable. One of the projects will, among other things, trial the use of a 5G-controlled robot to streamline the operation of taxiways and runways. “This is an exciting collaborative project for us, and we are proud to be allowed to contribute our 5G expertise to Avinor and together find out how new mobile technology can create

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 176 - 23 OCTOBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 175 - 23 OCTOBER 2023 On 10 August 2023, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 10 August 2023 up to and including no later than 31 October 2023. For details, please see announcement no. 112 of 10 August 2023.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 30 million (approximately DKK 204 million).

BioStock: Chordate Medical’s migraine treatment gets attention at congress

Recently, medtech company Chordate Medical participated in the prominent pain congress Deutsche Schmerzkongress in Mannheim, Germany. During the event, they experienced an increased interest in their migraine treatment Ozilia Migraine. This positive reception is expected to strengthen the company’s ongoing marketing activities in Germany, where they previously also conducted a successful patient study. To find out more about the market introduction in Germany and the highlights from the congress, BioStock contacted the company’s CEO Anders Weilandt.Read the full article at biostock.se:

TOMRA: Mandatory notification of trade

TOMRA's CEO Tove Andersen has today bought 5,550 shares in TOMRA Systems ASA at a price of NOK 85.50 per share. After the transaction, Tove Andersen holds 29,479 shares in TOMRA Systems ASA. Further disclosure details can be found in the attached form. Asker, 23 October 2023 TOMRA Systems ASA For further information, please contact: Daniel Sundahl, Head of Investor Relations, Tel: +47 91 36 18 99 This information is considered to be inside information pursuant to the EU Market Abuse Regulation (EU) No 596/2014 and is subject to the disclosure requirements pursuant to Section

Eevia Health Plc receives a 1 mSEK/94 kEUR sales order for a Bilberry extract product

Eevia Health Plc, (”Eevia” or ”The Company”), has received a 94 kEUR sales order from a European nutraceutical brand owner.The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements, as well as cosmetics in over 50.000 pharmacies, health food shops, and other retail outlets across 36 countries, including China and USA. The sales value to Eevia of this new order is 94 kEUR for Feno-Myrtillus® 1, which is a so-called 5:1 Extract. The product is a Bilberry extract standardized for anthocyanins and is a repeat order.

Wärtsilä Decarbonisation Modelling agreement supports Raízen’s commitment to reducing marine sector’s GHG emissions

Wärtsilä Corporation, Trade press release, 23 October 2023 at 10:00 AM EESTTechnology group Wärtsilä has signed a strategic partnership agreement for Decarbonisation Modelling  with Raízen, a major Brazilian energy company. The agreement focuses on both newbuilding and existing operation upgrade plans. Its aim is to build and implement a fleet-wide decarbonisation plan with a particular interest in the future marine introduction of ethanol as a marine fuel. Wärtsilä, under its fleet decarbonisation programme, has a strong track record in bringing new

Svenska Aerogel sales update: “Intensified focus on Transport and one more customer introducing product with Quartzene[®]”

Svenska Aerogel is intensifying its focus on the Transport industry – this is stated by CEO Tor Einar Norbakk as he gives a new sales update. The company is currently engaged in several ongoing customer projects related to battery safety for electric vehicles, and this is reflected in Svenska Aerogel’s customer segmentation strategy moving forward. Tor Einar Norbakk also provides updates on key customers, including one that has introduced a product incorporating Quartzene[®] and is preparing for launch.Svenska Aerogel has decided to focus on three primary customer segments going forward:

BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago’s CEO Mats Hansen.Read the interview with Mats Hansen at biostock.se: Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock This is a press release from BioStock -

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024.According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board. Work on composing the Nomination Committee is now completed, and this year’s Nomination Committee consists of: Karl Tobieson, appointed by Linc ABRichard Torgerson, appointed by Nordea Investment

Michigan Medicine harnesses the power of Sectra's digital pathology solution to enhance patient care and foster collaboration among physicians

Linköping, Sweden and Shelton, CT – October 23, 2023 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) announces that the US health and academic center Michigan Medicine is expanding its usage of Sectra’s enterprise imaging solution by including Sectra's module for digital pathology. This will enable their pathologists to review and collaborate around cases, ultimately improving cancer diagnostics in the region.Digital pathology leads to numerous advantages for hospitals, pathologists, and patients. With Sectra’s digital pathology

Circio Holding ASA - Notifation of shareholding

Pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations, we hereby disclose the following information on behalf of Atlas Special Opportunities, LLC. Atlas Special Opportunities, LLC ("Atlas") has on 20 October 2023 sold 123 738 shares in Circio Holding ASA. Atlas holds 274,457 shares in Circio, corresponding to 3.83% of the share capital and voting rights in Circio Holding ASA. This information is subject to the disclosure requirements pursuant to section 4 -3 of the Norwegian Securities Trading Act.

Buybacks of shares in ITAB during week 42 2023

During the period between 16 and 20 October 2023, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 38,417 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“MAR”)

Epiroc AB’s Nomination Committee for the Annual General Meeting 2024

Stockholm, Sweden: According to the Instruction for the Nomination Committee adopted by the Annual General Meeting of Epiroc AB, the Nomination Committee should consist of representatives for the four shareholders, directly registered or ownership grouped, controlling the largest number of votes in Epiroc AB that desire to appoint a member. In addition thereto, the Chairman of the Board of Directors shall be a member.The following persons will form the Nomination Committee for the Annual General Meeting 2024. Petra Hedengran - Investor AB (Chair)Joachim Spetz - Swedbank Robur funds

Freetrailer reaches one million rentals

For the first time in the company's history, Freetrailer Group A/S has passed one million rentals during the past 12 months. The record is mainly driven by significantly more locations with the company's partners and the roll-out of 1,275 new units during the period.Freetrailer Group A/S has set a new record in the number of rentals. Over the past 12 months, the use of the company's trailers and electric cargo bikes has reached one million, which corresponds to a continuous growth in the number of rentals of 22% compared to the previous 12 months.   Over the past year, the number of

Wulff Group Plc’s Interim Report for January 1 – September 30, 2023

INTERIM REPORT | OCTOBER 23, 2023 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Interim Report January 1–September 30, 2023. The complete report is attached to this stock exchange release as a pdf-file. The report is also available at the website www.wulff.fi. The third quarter fell short of expectations – operational programme will improve profitability 1.7.–30.9.2023 BRIEFLY · Net sales totalled EUR 21.2 million (24.0), decreased by 11.6% · EBITDA was EUR 0.8 million (1.7) and comparable EBITDA was EUR 1.1 million (1.7) · Operating profit (EBIT) was EUR 0.3

Catena Media announces share buybacks executed from 16 to 20 October 2023

Catena Media plc (LEI code: 549300609A73DL5C5Z86) repurchased 75,000 of its own ordinary shares (ISIN code: MT0001000109) from 16 to 20 October 2023 as part of its share buyback programme. The buyback programme was authorised by shareholders at an extraordinary general meeting on 12 July 2023 and initiated and announced by the board of directors on 17 July 2023. The programme is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Its purpose is to deliver

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023

Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Stephane Dalle, the top recruiting investigator of the ATLAS-IT-05 study, will give a poster presentation today at the ESMO 2023 Congress.ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 in combination with Keytruda® (pembrolizumab) in stage III-IV melanoma patients refractory to treatment with PD-1 / PD-L1 inhibitors.   The poster presents early preliminary clinical data from 20 patients (14 patients for efficacy)

Bulten AB nomination committee for 2024 AGM appointed

The Bulten Annual General Meeting will be held in Gothenburg, Sweden on Thursday April 25, 2024. Nomination committee members for the meeting have now been appointed.The nomination committee shall, according to the AGM’s decision, consist of four members: a representative for each of the three major shareholders on the last banking day in September who wish to appoint a member to the nomination committee, and the Chairman of the Board. The three major shareholders refer to those registered and ownership-grouped by Euroclear Sweden AB as of the last banking day in September. If any of the

AFRY awarded owner’s engineering services for a new waste-to-energy project in Malaysia

Worldwide PMC Sdn. Bhd. (WPMC) has awarded AFRY a contract to provide owner’s engineering services for a waste-to-energy project in Kuala Selangor, Malaysia, that will enable more efficient and sustainable municipal waste management.State-of-the-art waste-to-energy (WtE) facilities are an essential component for accelerating the transition to a sustainable future, as they are designed to recover the value of the waste that remains after reusing and recycling, and convert it into energy. The new plant in Malaysia will significantly reduce the amount of waste going to landfills and

There are no items matching the current filter
There are no more items matching the current filter
Back to top